Application of FCS Single-Molecule Analysis in Developing Novel Plasma Separation Technology

Research Overview

In clinical diagnostics and point-of-care testing (POCT), rapidly separating plasma from whole blood remains a critical challenge. Although traditional centrifugation is highly efficient, it falls short in scenarios requiring portability, ultra-small sample processing, or off-grid power supply.

To address this problem, a research team led by Prof. Yang Hui at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, published an innovative study in Microsystems & Nanoengineering, proposing a power-free plasma separation device based on negative magnetophoresis.

The core innovation of this device lies in its "long-short alternating dual-Halbach enhanced magnet array." This design enables efficient, static separation of blood cells from plasma within whole blood via magnetic forces—without requiring external power sources or precision pumps.

The team validated the separation efficiency through experiments with rat and human whole-blood samples. They successfully applied the device to rapid detection in simulated medicine metabolism assays (including fluorescent antibody concentration and hydrodynamic radius analyses) and COVID-19 IgG antibody detection. The results showed high consistency with traditional centrifugation, demonstrating that this device offers a low-cost, easy-to-operate solution for rapid biochemical analysis in resource-limited settings.

FCS Technology: The "Gold Standard" for Separation Quality Validation

To verify whether plasma separated via negative magnetophoresis is suitable for downstream pharmacokinetic (PK) analysis, the research team introduced a highly sensitive single-molecule detection technique: Fluorescence Correlation Spectroscopy (FCS).

Researchers mixed fluorescently labeled antibodies at various concentrations (10 nM, 20 nM, and 40 nM) into rat whole blood. Plasma was obtained through both negative magnetophoresis separation and standard two-step centrifugation, followed by comparative evaluation using FCS.

Core Findings:

• Particle Size Consistency: The apparent hydrodynamic radius ($\tau_D$ value) of the antibodies measured by FCS showed high consistency between the two groups, with a maximum variance of only 14.1%. This indicates that the negative magnetophoresis process is remarkably gentle, causing no antibody aggregation or degradation and preserving their native conformation.

• Concentration Accuracy: Antibody concentrations measured across both methods were exceptionally close, with a maximum variance of 16.3%. This confirms that negative magnetophoresis causes no specific protein loss or non-specific adsorption.

These findings strongly prove that negative magnetophoresis separation achieves quality equivalence with "gold standard" centrifugation, providing essential quality-control data for its deployment in rapid, reliable medicine concentration monitoring.

Figure 5: Rapid detection results of simulated medicine metabolism.

• a: Workflow of rat medicine metabolism testing;

• b–d: FCS detection results of fluorescent antibodies in plasma separated via magnetic separation vs. centrifugation at antibody concentrations of (b) 10 nM, (c) 20 nM, and (d) 40 nM;

• e: Comparison of fluorescent antibody concentration and τD values (a metric associated with antibody hydrodynamic size) in plasma samples following magnetic separation vs. centrifugation.

Why Is FCS's Technical Advantage Indispensable?

FCS played a crucial referee role in this study due to its distinct analytical capabilities:

1. Single-Molecule Sensitivity: Accurately quantifies fluorescent molecules within the pM to nM range, far surpassing conventional methods and making it ideal for tracking dynamic medicine concentrations in vivo.

2. Minimal Sample Requirement: Requires only 30 μL of plasma per assay. This is vital for small animal studies with strict blood volume limits, enabling multi-point serial sampling without compromising animal health.

3. Assay-Free In-Situ Measurement: FCS directly quantifies target molecules through fluorescence fluctuations within a confocal volume—even in the presence of complex proteins, lipids, or residual magnetic nanoparticles—eliminating purification-induced errors and recovery losses.

4. Simultaneous Concentration & Size Analysis: Beyond concentration, FCS determines diffusion coefficients (τD), which serve as key metrics to assess medicine aggregation or degradation state—an analytical dimension unachievable through basic fluorometry.

5. Rapid High-Throughput Performance: Single measurements are completed in as fast as 10 seconds, making it well-suited for processing animal samples across multiple time points and cohorts in high-throughput pharmacokinetic studies.

Research Significance & FCS Application Prospects

This study marks the first integration of an enhanced dual-Halbach magnet array with static negative magnetophoresis to create a truly "passive, pump-free, highly adaptable" plasma separation platform. It overcomes traditional reliance on external power and bulky equipment while delivering excellent separation efficiency and downstream assay compatibility.

Throughout this work, FCS served as an irreplaceable benchmark, providing quantitative proof of negative magnetophoresis reliability and sample integrity. This methodological groundwork supports future applications in fluorescence-based pharmacokinetics, biomarker detection, and therapeutic medicine monitoring (TDM). As single-molecule detection becomes more accessible, pairing FCS with portable plasma separation devices promises to unlock a new generation of minimally invasive, point-of-care, and precise clinical diagnostic solutions.

About FCS Technology

Fluorescence Correlation Spectroscopy (FCS) measures molecular/nanoparticle characteristics—such as molar concentration, brightness/aggregation state, diffusion coefficient/hydrodynamic radius, and binding affinity (K_D values)—at single-molecule resolution within micro-volume samples (~μL) or living cells. As a homogeneous, in-situ, high-content analytical tool, FCS is fully compatible with physiological matrices (including cell lysates and whole blood).

FCS and its derivative techniques are widely utilized in cell signaling, liquid-liquid phase separation (LLPS), biomolecular denaturation/aggregation, structure-function mechanisms, nanomedicine development, exosome analysis, fluorescent probe engineering, antibody/medicine screening, and microfluidics. To date, over 15,000 academic papers leveraging FCS have been indexed in PubMed.

About the JLM-Lifetech FCS Biomolecular Interaction Analyzer

The MIA Series FCS Molecular Interaction Analyzer for Single-molecule Kinetics is an ultra-sensitive single-molecule platform based on Fluorescence Correlation Spectroscopy (FCS). By detecting fluorescence intensity fluctuations within a microscopic observation volume, it characterizes biomolecular interactions and properties at the single-molecule level.

Utilizing correlation algorithms to resolve time-domain signals, the system requires no separation or purification steps (homogeneous detection). With sample volumes of just a few dozen microliters, it delivers high-throughput quantitative analysis of concentration, particle size, diffusion coefficient, and binding affinity (K_D) within seconds.

Primary Application Fields:

• medicine Discovery & Development

• Cell Biology

• Chemistry

• Biochemistry & Molecular Biology

• Structural Biology

• Photophysics